CALL FOR PAPERS Biomarkers in Lung Diseases: from Pathogenesis to Prediction to New Therapies Pharmacological targeting of VEGFR signaling with axitinib inhibits Tsc2-null lesion growth in the mouse model of lymphangioleiomyomatosis

Elena N. Atochina-Vasserman, Elena Abramova, Melane L. James, Ryan Rue, Amy Y. Liu, Nathan Tessema Ersumo, Chang-Jiang Guo, Andrew J. Gow, and Vera P. Krymskaya Airway Biology Initiative, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; Pulmonary, Allergy and Critical Care Division, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania; and Department of Pharmacology & Toxicology, Rutgers University, Piscataway, New Jersey

[1]  Krister Wennerberg,et al.  Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation , 2015, Nature.

[2]  A. Gow,et al.  Surfactant dysfunction and lung inflammation in the female mouse model of lymphangioleiomyomatosis. , 2014, American journal of respiratory cell and molecular biology.

[3]  A. Gow,et al.  Folliculin controls lung alveolar enlargement and epithelial cell survival through E-cadherin, LKB1, and AMPK. , 2014, Cell reports.

[4]  S. Stacker,et al.  Lymphangiogenesis and lymphatic vessel remodelling in cancer , 2014, Nature Reviews Cancer.

[5]  Andrew J. Gow,et al.  NOS2 Is Critical to the Development of Emphysema in Sftpd Deficient Mice but Does Not Affect Surfactant Homeostasis , 2014, PloS one.

[6]  M. Schmidinger.  Understanding and managing toxicities of vascular endothelial growth factor (VEGF) inhibitors , 2013, EJC supplements : EJC : official journal of EORTC, European Organization for Research and Treatment of Cancer ... [et al.].

[7]  Charlie Strange,et al.  Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial. , 2013, The Lancet. Respiratory medicine.

[8]  A. Husain,et al.  Lymphatic Endothelial Differentiation in Pulmonary Lymphangioleiomyomatosis Cells , 2013, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  S. Srinivas,et al.  The frequency and severity of cardiovascular toxicity from targeted therapy in advanced renal cell carcinoma patients. , 2013, JACC. Heart failure.

[10]  W. Travis,et al.  Lymphangioleiomyomatosis: calling it what it is: a low-grade, destructive, metastasizing neoplasm. , 2012, American journal of respiratory and critical care medicine.

[11]  E. Henske,et al.  Lymphangioleiomyomatosis - a wolf in sheep's clothing. , 2012, The Journal of clinical investigation.

[12]  T. Colby,et al.  Prevention of Alveolar Destruction and Airspace Enlargement in a Mouse Model of Pulmonary Lymphangioleiomyomatosis (LAM) , 2012, Science Translational Medicine.

[13]  Brion W. Murray,et al.  Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors , 2012, Proceedings of the National Academy of Sciences.

[14]  Tara Karnezis,et al.  VEGF-D promotes tumor metastasis by regulating prostaglandins produced by the collecting lymphatic endothelium. , 2012, Cancer cell.

[15]  A. Gow,et al.  Early alveolar epithelial dysfunction promotes lung inflammation in a mouse model of Hermansky-Pudlak syndrome. , 2011, American journal of respiratory and critical care medicine.

[16]  E. Goncharova,et al.  mTORC2 Is Required for Proliferation and Survival of TSC2-Null Cells , 2011, Molecular and Cellular Biology.

[17]  W. Linehan,et al.  Serum vascular endothelial growth factor-D prospectively distinguishes lymphangioleiomyomatosis from other diseases. , 2010, Chest.

[18]  J. Myers,et al.  Vascular endothelial growth factors C and D induces proliferation of lymphangioleiomyomatosis cells through autocrine crosstalk with endothelium. , 2009, The American journal of pathology.

[19]  J. Moss,et al.  Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement. , 2009, Chest.

[20]  A. Gow,et al.  Immune Reconstitution during Pneumocystis Lung Infection: Disruption of Surfactant Component Expression and Function by S-Nitrosylation1 , 2009, The Journal of Immunology.

[21]  P. O'Connor,et al.  Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3 , 2008, Clinical Cancer Research.

[22]  Ying Lu,et al.  AG-013736, a novel inhibitor of VEGF receptor tyrosine kinases, inhibits breast cancer growth and decreases vascular permeability as detected by dynamic contrast-enhanced magnetic resonance imaging. , 2007, Magnetic resonance imaging.

[23]  Y. Fukuchi,et al.  Vascular endothelial growth factor-D is increased in serum of patients with lymphangioleiomyomatosis. , 2006, Lymphatic research and biology.

[24]  S. Stacker,et al.  Lymphatic vessels in cancer metastasis: bridging the gaps. , 2006, Carcinogenesis.

[25]  Dai Fukumura,et al.  Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. , 2006, Cancer research.

[26]  D. Noonan,et al.  Modulation of cell migration and invasiveness by tumor suppressor TSC2 in lymphangioleiomyomatosis. , 2006, American journal of respiratory cell and molecular biology.

[27]  M. Skobe,et al.  Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. , 2006, Cancer research.

[28]  Y. Fukuchi,et al.  Lymphangiogenesis-Mediated Shedding of LAM Cell Clusters as a Mechanism for Dissemination in Lymphangioleiomyomatosis , 2005, The American journal of surgical pathology.

[29]  R. Herbst,et al.  Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  K. Alitalo,et al.  Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. , 2005, Cancer research.

[31]  D. Noonan,et al.  TSC2 modulates actin cytoskeleton and focal adhesion through TSC1-binding domain and the Rac1 GTPase , 2004, The Journal of cell biology.

[32]  J. Brugarolas,et al.  Dysregulation of HIF and VEGF is a unifying feature of the familial hamartoma syndromes. , 2004, Cancer cell.

[33]  William R Sellers,et al.  TSC2 regulates VEGF through mTOR-dependent and -independent pathways. , 2003, Cancer cell.

[34]  K. Alitalo,et al.  Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. , 2002, Journal of the National Cancer Institute.

[35]  K. Alitalo,et al.  Multiple Forms of Mouse Vascular Endothelial Growth Factor-D Are Generated by RNA Splicing and Proteolysis* , 2001, The Journal of Biological Chemistry.

[36]  T. Veikkola,et al.  Signalling via vascular endothelial growth factor receptor‐3 is sufficient for lymphangiogenesis in transgenic mice , 2001, The EMBO journal.

[37]  Steven A. Stacker,et al.  VEGF-D promotes the metastatic spread of tumor cells via the lymphatics , 2001, Nature Medicine.

[38]  S. Lipton,et al.  Three Pairs of Cysteine Residues Mediate Both Redox and Zn2+ Modulation of the NMDA Receptor , 2001, The Journal of Neuroscience.

[39]  T. Noda,et al.  Renal carcinogenesis, hepatic hemangiomatosis, and embryonic lethality caused by a germ-line Tsc2 mutation in mice. , 1999, Cancer research.

[40]  K. Alitalo,et al.  Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  K. Alitalo,et al.  A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases. , 1996, The EMBO journal.

[42]  K. Kang,et al.  Mitochondria protection of baicalein against oxidative damage via induction of manganese superoxide dismutase. , 2011, Environmental toxicology and pharmacology.

[43]  U. Holmskov,et al.  Viral aggregating and opsonizing activity in collectin trimers. , 2010, American journal of physiology. Lung cellular and molecular physiology.

[44]  V. Krymskaya.  Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis. , 2008, Proceedings of the American Thoracic Society.

[45]  J. Partanen,et al.  Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins , 2004, Nature Immunology.